PUBLIC COMPANY
save$TNYATenaya Therapeutics, Inc.
$TNYASouth San Francisco, CA, USupdated 2mo ago
community read0 votes
pipeline
3
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
1Phase 12Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- —Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy
- phase2Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
- phase1Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC
- —Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 58m ago
Found something off?
comments(0)
5-min edit window · permanent after that